CPhI Online

- Biopharma News

FDB to triple UK microbial production capacity as Fujifilm commits to $83 million investment

19 Mar 2020

Fujifilm Diosynth Biotechnologies will triple microbial production capacity at its UK Teesside facility after joint owner Fujifilm Corporation pledged to invest 9 billion yen (USD83 million) in the biologics focused CDMO.

The expansion – scheduled to be operational by 2022 -- will include a new production line with 2 X 2000L fermenters and a modular purification suite and an upgrade to utilities to make them ready for high volume production.

"Fujifilm has committed to supporting the biopharmaceutical industry and invested aggressively in both capital and technology for producing such as antibodies and gene therapies,” said Takatoshi Ishikawa, executive vice president and general manager of the Bio CDMO Division of Fujifilm.

He added that the expansion was a response to current increased demand for microbial production.

“From our pAVEway expression technology to our commercial capabilities, we are well suited to support customers at all stages of the product development process,” said Paul Found, chief operating officer, FDB, United Kingdom.

Fujifilm said it is targeting sales of 100 billion yen in the Bio CDMO business – which offers both biopharmaceuticals and small molecule pharmaceuticals -- in FY2021.

FDB is a joint venture between Fujifilm and Mitsubishi Corporation and also has sites in Texas and North Carolina in the US and Hillerød, Denmark.

Related Content